Deal of the Day — limited-time pharmacy picks!
Brcaone 100mg Tablet

Brcaone 100mg Tablet

Prescription requiredRx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

60 Tablets in Bottle

About The Product

Ovarian Cancer, Breast Cancer


Description

Brcaone 100mg tablet is a an anti-cancer medication. This treatment approach treats ovarian and breast cancer by blocking the PARP enzyme which is the primary cause of cancer formation in the body.

Its active ingredient is Olaparib that contains PARP enzyme which prevent cancer cells from multiplying and help stop the spread of cancer in the body. The dose and duration must be prescribed by the healthcare professional, as it is not recommended to the adults under the age of 18.

Strict adherence to the prescribed regimen is essential to ensure the effectiveness of the treatment.

Indication

Breast cancer and ovarian cancer

Common Side Effects

  • Brcaone 100mg tablet cause various side effects like any other medication, do not self administer on any of the doses.
  • It is better to consult with the doctor if any of these symptoms persist: ● Muscle cramps ● Confusion, visual disturbances, seizures, and headache ● Breathlessness ● Swelling of feet ● Changes in heartbeat ● High blood pressure ● Pneumonia ● Loss of appetite ● Sensitivity, tingling and burning sensation of the skin ● Nausea, vomiting, and diarrhea ● Mouth ulcers ● Constipation

Dosage And Duration

  • Brcaone 100mg tablet is used under doctor prescription.
  • Most of the healthcare professionals prescribed the tablet with or without the food at the fixed time everyday to enhance the effectiveness of the treatment.
  • Do not skip or stop the medication without the consultation of a healthcare provider.
  • Always follow the prescribed dosage and schedule carefully to ensure the best result and reduce the side effects of the treatment.

Mechanism Of Action

Breast and ovarian cancer is formed by the mutation in genetic such as BRC1 and BRC2, which normally help regulate cell growth repair damaged DNA. These genetic mutations disrupt normal cell function, leading to uncontrolled cell growth and tumor formation.

Brcaone 100mg tablet is a targeted therapy contains PARP inhibitor enzyme which directly attacks on the cancer cell growth and stop the formation of tumor size in the body. The medicine also improves the immune function through that body can fight off the other diseases as well.

Safety Advice

Alcohol
Taking Brcaone 100mg tablet with alcohol is may be dangerous to the patient health but consult the doctor before taking the medication.
Driving
Brcaone 100mg tablet may not cause dizziness or sleepiness but patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.
Pregnancy
Brcaone 100mg tablet is not recommended to pregnant and breastfeeding women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.
Kidney
Kidney patients should take precautions while using Brcaone 100mg tablet as dose adjustment and doctor's prescription is much needed.
Liver
Brcaone 100mg tablet may interrupt with liver function. Patients with liver disease should consult the doctor before using it.

Reference

• Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., ... & Matulonis, U. (2012).

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366(15), 1382-1392. • Forster, M.

D., Dedes, K. J., Sandhu, S., Frentzas, S., Kristeleit, R., Ashworth, A., ... & Molife, L.

R. (2011).

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature reviews Clinical oncology, 8(5), 302-306. • Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.

J., ... & Kindler, H. L.

(2019). Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

New England Journal of Medicine, 381(4), 317-327. • Oza, A. M., Cibula, D., Benzaquen, A.

O., Poole, C., Mathijssen, R. H., Sonke, G.

S., ... & Friedlander, M. (2015).

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The lancet oncology, 16(1), 87-97. • Clarke, N.

W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., ... & Saad, F.

(2022). Abiraterone and olaparib for metastatic castration-resistant prostate cancer.

NEJM evidence, 1(9), EVIDoa2200043.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026